Näytä suppeat kuvailutiedot

dc.contributor.authorKarjula, Topias
dc.contributor.authorKemi, Niko
dc.contributor.authorNiskakangas, Anne
dc.contributor.authorMustonen, Olli
dc.contributor.authorPuro, Iiris
dc.contributor.authorPohjanen, Vesa-Matti
dc.contributor.authorKuopio, Teijo
dc.contributor.authorElomaa, Hanna
dc.contributor.authorAhtiainen, Maarit
dc.contributor.authorMecklin, Jukka-Pekka
dc.contributor.authorSeppälä, Toni T.
dc.contributor.authorWirta, Erkki-Ville
dc.contributor.authorSihvo, Eero
dc.contributor.authorVäyrynen, Juha P.
dc.contributor.authorYannopoulos, Fredrik
dc.contributor.authorHelminen, Olli
dc.date.accessioned2023-06-16T11:02:00Z
dc.date.available2023-06-16T11:02:00Z
dc.date.issued2023
dc.identifier.citationKarjula, T., Kemi, N., Niskakangas, A., Mustonen, O., Puro, I., Pohjanen, V.-M., Kuopio, T., Elomaa, H., Ahtiainen, M., Mecklin, J.-P., Seppälä, T. T., Wirta, E.-V., Sihvo, E., Väyrynen, J. P., Yannopoulos, F., & Helminen, O. (2023). The prognostic role of tumor budding and tumor-stroma ratio in pulmonary metastasis of colorectal carcinoma. <i>European Journal of Surgical Oncology</i>, <i>49</i>(7), 1298-1306. <a href="https://doi.org/10.1016/j.ejso.2023.02.009" target="_blank">https://doi.org/10.1016/j.ejso.2023.02.009</a>
dc.identifier.otherCONVID_177015431
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/87870
dc.description.abstractObjective To evaluate the prognostic value of tumor budding and tumor-stroma ratio (TSR) in resected pulmonary metastases of colorectal carcinoma (CRC). Methods In total, 106 pulmonary metastasectomies were performed to 74 patients in two study hospitals during 2000–2020. All relevant clinical data were retrospectively collected. Tumor budding based on the International Tumor Budding Consensus Conference recommendations and TSR in the first resected pulmonary metastases and primary tumors were evaluated from diagnostic hematoxylin-eosin-stained histopathological slides. Results 60 patients (85.7%) had low tumor budding (≤5 buds/field) and 10 patients (14.3%) had high tumor budding (>5 buds/field) in their first pulmonary metastases of CRC. 5-year overall survival rates of pulmonary metastasectomy in low and high total tumor budding were 28.3% and 37.3% (p = 0.387), respectively. 19 patients (27.1%) had low TSR and 51 patients (72.9%) had high TSR. The 5-year overall survival rates were 32.9% in low and 28.6% in high TSR of first pulmonary metastases (p = 0.746). Tumor budding and TSR did not provide prognostic value in Cox multivariate analysis. Tumor budding and TSR in resected pulmonary metastases were not associated with those of the primary tumor. Conclusion Tumor budding and TSR in the resected pulmonary metastases of CRC showed no statistically significant prognostic value, however, additional well-powered confirmatory studies are needed.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesEuropean Journal of Surgical Oncology
dc.rightsCC BY 4.0
dc.subject.othercolorectal cancer
dc.subject.otherpulmonary metastases
dc.subject.othertumor budding
dc.subject.othertumor-stroma ratio
dc.titleThe prognostic role of tumor budding and tumor-stroma ratio in pulmonary metastasis of colorectal carcinoma
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202306163925
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosMatemaattis-luonnontieteellinen tiedekuntafi
dc.contributor.laitosBio- ja ympäristötieteiden laitosfi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.laitosFaculty of Mathematics and Scienceen
dc.contributor.laitosDepartment of Biological and Environmental Scienceen
dc.contributor.oppiaineSolu- ja molekyylibiologiafi
dc.contributor.oppiaineCell and Molecular Biologyen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.format.pagerange1298-1306
dc.relation.issn0748-7983
dc.relation.numberinseries7
dc.relation.volume49
dc.type.versionpublishedVersion
dc.rights.copyright© 2023 The Authors. Published by Elsevier Ltd.
dc.rights.accesslevelopenAccessfi
dc.subject.ysoetäpesäkkeet
dc.subject.ysosyöpätaudit
dc.subject.ysopaksusuolisyöpä
dc.subject.ysokeuhkot
dc.subject.ysoennusteet
dc.subject.ysokarsinoomat
dc.subject.ysokasvaimet
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p2298
jyx.subject.urihttp://www.yso.fi/onto/yso/p678
jyx.subject.urihttp://www.yso.fi/onto/yso/p5937
jyx.subject.urihttp://www.yso.fi/onto/yso/p3185
jyx.subject.urihttp://www.yso.fi/onto/yso/p3297
jyx.subject.urihttp://www.yso.fi/onto/yso/p28373
jyx.subject.urihttp://www.yso.fi/onto/yso/p2299
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.1016/j.ejso.2023.02.009
jyx.fundinginformationThis study was funded by Instrumentarium Science Foundation (O.H), Mary and Georg C. Ehrnrooth Foundation (O.H) and Finnish State Research Funding (O.H, J-P.M), Cancer Foundation Finland (J.P.V), J&A Erkko Foundation (J-P.M). The funding sources had no involvement in the study design, collection of data, analysis and interpretation of the data, in writing the report or submitting decision of the article.
dc.type.okmA1


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot

CC BY 4.0
Ellei muuten mainita, aineiston lisenssi on CC BY 4.0